The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens

Psychopharmacology

Volumn 231, Issue 23, 2014, Pages 4541-4551

  Huang, Mei ^a   Felix, Anna R ^a   Flood, Dorothy G ^b   Bhuvaneswaran, Chaya ^b   Hilt, Dana ^b   Koenig, Gerhard ^b   Meltzer, Herbert Y ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FORUM Pharmaceuticals   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acetylcholine; Dopamine; EVP 6124; Glutamate; 7 nicotinic acetylcholine receptor

Indexed keywords

ACETYLCHOLINE; BUNGAROTOXIN RECEPTOR; DOPAMINE; ENCENICLINE; GLUTAMIC ACID; METHYLLYCACONITINE; 4 AMINOBUTYRIC ACID; 7-CHLORO-N-QUINUCLIDIN-3-YL-BENZO(B)THIOPHENE-2-CARBOXAMIDE; ACONITINE; NICOTINIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINE DERIVATIVE; THIOPHENE DERIVATIVE;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ACETYLCHOLINE BRAIN LEVEL; AMINE TRANSPORT; AMINO ACID BRAIN LEVEL; AMINO ACID TRANSPORT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; COGNITION; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE UPTAKE; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG RECEPTOR BINDING; GABAERGIC TRANSMISSION; HIPPOCAMPUS; IN VIVO STUDY; MALE; MEDIAL PREFRONTAL CORTEX; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; METABOLISM; PREFRONTAL CORTEX; SPRAGUE DAWLEY RAT;

ACETYLCHOLINE; ACONITINE; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; MALE; MICRODIALYSIS; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; QUINUCLIDINES; RATS; RATS, SPRAGUE-DAWLEY; THIOPHENES;

EID: 84920851957     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3596-0     Document Type: Article

References (61)

1. Arnold HM, Nelson CL, Sarter M, Bruno JP (2003) Sensitization of cortical acetylcholine release by repeated administration of nicotine in rats. Psychopharmacology (Berl) 165(4):346-358
2. Arvanov VL, Wang RY (1998) M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-Aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 18(3):197-209
3. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY (1997) Clozapine and haloperidol modulate N-methyl-D-Aspartate-And non-N-methyl-D-Aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283(1): 226-234
4. Biton B, Bergis OE, Galli F, Nedelec A, Lochead AW, Jegham S, Godet D, Lanneau C, Santamaria R, Chesney F, Léonardon J, Granger P, DebonoMW, Bohme GA, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Vigé X, Voltz C, Rouquier L, Souilhac J, Santucci V, Gueudet C, Françon D, Steinberg R, Griebel G, Oury-Donat F, George P, Avenet P, Scatton B (2007) SSR180711, a novel selective ?7 nicotinic receptor partial agonist: (I) binding and functional profile. Neuropsychopharmacology 32(1):1-16
5. Boess FG, De Vry J, Erb C, Flessner T, HendrixM, Luithle J, Methfessel C, Riedl B, Schnizler K, van der Staay FJ, van Kampen M, Wiese WB, Koenig G (2007) The novel ?7 nicotinic acetylcholine receptor agonist N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther 321(2): 716-725
6. Bortz DM, Mikkelsen JD, Bruno JP (2013) Localized infusions of the partial alpha 7 nicotinic receptor agonist SSR180771 evoke rapid and transient increases in prefrontal glutamate release. Neuroscience 255:55-67
7. Bourdelais AJ, Deutch AY (1994) The effects of haloperidol and clozapine on extracellular GABA levels in the prefrontal cortex of the rat: an in vivo microdialysis study. Cereb Cortex 4(1):69-77
8. Burton S (2006) Symptom domains of schizophrenia: the role of atypical antipsychotic agents. J Psychopharmacol 20(6 Suppl):6-19
9. Callahan PM, McNicholas KL, Ilch C, Rowe WB, Brucato FA, Kogan JH, Rose GM (2003) Characterization of nicotinic ?7 receptor agonists in animal models of cognition. Society for Neuroscience 2003 Annual Meeting, 615: 8/CC4
10. Chen JP, van Praag HM, Gardner EL (1991)Activation of 5-HT3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens. Brain Res 543(2):354-357
11. Chen L, Yamada K, Nabeshima T, Sokabe M (2006) Alpha7 nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-Amyloid infused rats. Neuropharmacology 50(2):254-268
12. Costall B, Naylor RJ (2004) 5-HT3 receptors. Curr Drug Targets CNS Neurol Disord 3(1):27-37
13. Coyle JT (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26(4-6):365-384
14. Daly DA,Moghaddam B (1993) Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatumof conscious rats. Neurosci Lett 152(1-2):61-64
15. Désaméricq G, Schurhoff F, Meary A, Szöke A, Macquin-Mavier I, Bachoud-Lévi AC, Maison P (2014) Long-term neurocognitive effects of antipsychotics in schizophrenia: a network metaanalysis. Eur J Clin Pharmacol 70(2):127-134
16. Di Matteo V, Pierucci M, Esposito E (2004) Selective stimulation of serotonin2c receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration. J Neurochem 89(2):418-429
17. Diez-Ariza M, Garcia-Alloza M, Lasheras B, Del Rio J, Ramirez MJ (2002) GABA(A) receptor antagonists enhance cortical acetylcholine release induced by 5-HT(3) receptor blockade in freely moving rats. Brain Res 956(1):81-85
18. Farber L, Haus U, Spath M, Drechsler S (2004) Physiology and pathophysiology of the 5-HT3 receptor. Scand J Rheumatol 119(Suppl): 2-8
19. Freedman R, Goldowitz D (2010) Studies on the hippocampal formation: from basic development to clinical applications: studies on schizophrenia. Prog Neurobiol 90(2):263-275
20. Gioanni Y, Rougeot C, Clarke PB, Lepousé C, Thierry AM, Vidal C (1999) Nicotinic receptors in the rat prefrontal cortex: increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission. Eur J Neurosci 11(1):18-30
21. Giovannini MG, Ceccarelli I, Molinari B, Cecchi M, Goldfarb J, Blandina P (1998) Serotonergic modulation of acetylcholine release from cortex of freely moving rats. J Pharmacol Exp Ther 285(3): 1219-1925
22. Gurley DA, Lanthorn TH (1998) Nicotinic agonists competitively antagonize serotonin at mouse 5-HT3 receptors expressed in Xenopus ooctyes. Neurosci Lett 247(2-3):107-110
23. Heresco-Levy U (2005) Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia. Expert Opin Emerg Drugs 10:827-844
24. Huang M, Felix AR, Kwon S, Lowe D, Wallace T, Santarelli L, Meltzer HY (2014a) The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release. Psychopharmacology (Berl). 231(10): 2199-2210. doi:10.1007/s00213-013-3373-5
25. Huang M, Panos JJ, Kwon S, Oyamada Y, Rajagopal L, Meltzer HY (2014b) Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism. J Neurochem 128(6):938-949
26. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY (2002) Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine efflux without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26:325-339
27. Kashkin VA, De Witte P (2005) Nicotine increases microdialysate brain amino acid concentrations and induces conditioned place preference. Eur Neuropsychopharmacol 15(6):625-632
28. Kurata K, Ashby CR Jr., Oberlender R, Tanii Y, Kurachi M, Rini NJ, Strecker RE (1996) The characterization of the effect of locally applied N-methylquipazine, a 5-HT3 receptor agonist, on extracellular dopamine levels in the anterior medial prefrontal cortex in the rat: an in vivo microdialysis study. Synapse 24(4):313-321
29. Kuroki T, Meltzer HY, Ichikawa J (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288:774-781
30. Leiser SC, Bowlby MR, Comery TA, Dunlop J (2009) A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol Ther 122(3):302-311
31. Levin ED, McClernon FJ, Rezvani AH (2006) Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 184(3-4):523-539
32. Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, Duan N, Hosford DA (2013) A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 38(6):968-975
33. Liu Q, Li Z, Ding JH, Liu SY, Wu J, Hu G (2006) Iptakalim inhibits nicotine-induced enhancement of extracellular dopamine and glutamate levels in the nucleus accumbens of rats. Brain Res 1085(1): 138-143
34. Livingstone PD, Dickinson JA, Srinivasan J, Kew JN, Wonnacott S (2010) Glutamate-dopamine crosstalk in the rat prefrontal cortex is modulated by alpha7 nicotinic receptors and potentiated by PNU-120596. J Mol Neurosci 40(1-2):172-176
35. Maricq AV, Peterson AS, Brake AJ,Myers RM, Julius D (1991) Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 254(5030):432-437
36. Martin LF, Kem WR, Freedman R (2004) Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl) 174:54-64
37. Maura G, Andrioli GC, Cavazzani P, Raiteri M (1992) 5-Hydroxytryptamine3 receptors sited on cholinergic axon terminals of human cerebral cortexmediate inhibition of acetylcholine release. J Neurochem 58(6):2334-2337
38. Meltzer HY, Huang M (2008) In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 72: 177-197
39. Mylecharane EJ (1996) Ventral tegmental area 5-HT receptors: mesolimbic dopamine release and behavioural studies. Behav Brain Res 73(1-2):1-5
40. O'Neill HC, Rieger K, Kem WR, Stevens KE (2003) DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats. Psychopharmacology (Berl) 169(3-4):332-339
41. ObinuMC, ReibaudM,Miquet JM, PasquetM, Rooney T (2002) Brainselective stimulation of nicotinic receptors by TC-1734 enhances ACh transmission from frontoparietal cortex and memory in rodents. Prog Neuropsychopharmacol Biol Psychiatry 26(5):913-918
42. Pasumarthi RK, Fadel J (2010) Stimulation of lateral hypothalamic glutamate and acetylcholine efflux by nicotine: implications for mechanisms of nicotine-induced activation of orexin neurons. J Neurochem 113(4):1023-1035
43. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic, New York
44. Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, Oury-Donat F, Avenet P, Griebel G, Scatton B (2007) SSR180711, a novel selective ?7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32(1):17-34
45. Preskorn SH, GawrylM, Dgetluck N, PalfreymanM, Bauer LO, Hilt DC (2014) Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract 20(1):12-24
46. Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, Reneerkens OAH, Flood DG, Hilt D, Gawryl M, Bertrand S, Bertrand D, König G (2012) EVP-6124, a novel and selective ?7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of ?7 nicotinic acetylcholine receptors. Neuropharmacology 62(2):1099-1110
47. Reid RT, Lloyd GK, Rao TS (1999) Pharmacological characterization of nicotine-induced acetylcholine release in the rat hippocampus in vivo: evidence for a permissive dopamine synapse. Br J Pharmacol 127(6):1486-1494
48. Reid MS, Fox L, Ho LB, Berger SP (2000) Nicotine stimulation of extracellular glutamate levels in the nucleus accumbens: neuropharmacological characterization. Synapse 35(2):129-136
49. Rossi S, Singer S, Shearman E, Sershen H, Lajtha A (2005) The effects of cholinergic and dopaminergic antagonists on nicotineinduced cerebral neurotransmitter changes. Neurochem Res 30(4):541-558
50. Schilström B, Fagerquist MV, Zhang X, Hertel P, Panagis G, Nomikos GG, Svensson TH (2000) Putative role of presynaptic alpha7 nicotinic receptors in nicotine stimulated increases of extracellular levels of glutamate and aspartate in the ventral tegmental area. Synapse 38(4):375-383
51. Singer S, Rossi S, Verzosa S, Hashim A, Lonow R, Cooper T, Sershen H, Lajtha A (2004) Nicotine-induced changes in neurotransmitter levels in brain areas associated with cognitive function. Neurochem Res 29(9):1779-1792
52. Summers KL, Kem WR, Giacobini E (1997) Nicotinic agonist modulation of neurotransmitter levels in the rat frontoparietal cortex. Jpn J Pharmacol 74(2):139-146
53. Tani Y, Saito K, Imoto M, Ohno T (1998) Pharmacological characterization of nicotinic receptor-mediated acetylcholine release in rat brain-An in vivo microdialysis study. Eur J Pharmacol 351(2): 181-188
54. Thompson AJ, Lummis SCR (2007) The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets 11(4):527-540
55. Thomsen MS, Hansen HH, Timmerman DB, Mikkelsen JD (2010) Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des 16(3):323-343
56. Toth E (1996) Effect of nicotine on the level of extracellular amino acids in the hippocampus of rat. Neurochem Res 21(8):903-907
57. Wallace TL, Callahan PM, Tehim A, Bertrand D, Tombaugh G, Wang XW, RoweWB,OngV, GrahamE, TerryAVJr., Rodefer JS,Herbert B, Murray M, Porter R, Santarelli L, Lowe DA (2011) RG3487, a novel nicotinic ?7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther 336(1):242-253
58. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005) A metaanalysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8(3):457-472
59. Yamamoto BK, Pehek EA, Meltzer HY (1994) Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiatry 55(Suppl B):8-14
60. Zanaletti R, Bettinetti L, Castaldo C, Cocconcelli G, Comery T, Dunlop J, Gaviraghi G, Ghiron C, Haydar SN, Jow F, Maccari L, Micco I, Nencini A, Scali C, Turlizzi E, Valacchi M (2012) Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789). J Med Chem 55(10):4806-4823
61. Zoheir N, Lappin DF, Nile CJ (2012) Acetylcholine and the alpha 7 nicotinic receptor: a potential therapeutic target for the treatment of periodontal disease? Inflamm Res 61(9):915-926